- Home
- GUTS vs ATOS Comparison
GUTS vs ATOS Comparison
Compare GUTS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- ATOS
- Stock Information
- Founded
- GUTS 2010
- ATOS 2009
- Country
- GUTS United States
- ATOS United States
- Employees
- GUTS N/A
- ATOS N/A
- Industry
- GUTS
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- ATOS Health Care
- Exchange
- GUTS NYSE
- ATOS Nasdaq
- Market Cap
- GUTS 110.1M
- ATOS 113.7M
- IPO Year
- GUTS 2024
- ATOS 2012
- Fundamental
- Price
- GUTS $1.80
- ATOS $0.83
- Analyst Decision
- GUTS Buy
- ATOS Strong Buy
- Analyst Count
- GUTS 2
- ATOS 3
- Target Price
- GUTS $18.00
- ATOS $7.00
- AVG Volume (30 Days)
- GUTS 382.2K
- ATOS 886.8K
- Earning Date
- GUTS 02-02-2025
- ATOS 11-12-2024
- Dividend Yield
- GUTS N/A
- ATOS N/A
- EPS Growth
- GUTS N/A
- ATOS N/A
- EPS
- GUTS N/A
- ATOS N/A
- Revenue
- GUTS $97,000.00
- ATOS N/A
- Revenue This Year
- GUTS N/A
- ATOS N/A
- Revenue Next Year
- GUTS N/A
- ATOS N/A
- P/E Ratio
- GUTS N/A
- ATOS N/A
- Revenue Growth
- GUTS N/A
- ATOS N/A
- 52 Week Low
- GUTS $1.74
- ATOS $0.77
- 52 Week High
- GUTS $14.50
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- GUTS 40.50
- ATOS 27.85
- Support Level
- GUTS $1.91
- ATOS $0.91
- Resistance Level
- GUTS $2.10
- ATOS $0.94
- Average True Range (ATR)
- GUTS 0.16
- ATOS 0.06
- MACD
- GUTS -0.01
- ATOS -0.00
- Stochastic Oscillator
- GUTS 6.12
- ATOS 1.62
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.